| 1 |
31331862 | Metastatic Renal Cell Carcinoma Rapidly Progressive to Sunitinib: What to Do Next? | 2021 Apr |
1 |
| 2 |
33995090 | Sodium-Glucose CoTransporter-2 Inhibitor Empagliflozin Ameliorates Sunitinib-Induced Cardiac Dysfunction via Regulation of AMPK-mTOR Signaling Pathway-Mediated Autophagy. | 2021 |
2 |
| 3 |
32232883 | Potential new therapy of Rapalink-1, a new generation mammalian target of rapamycin inhibitor, against sunitinib-resistant renal cell carcinoma. | 2020 May |
1 |
| 4 |
31031856 | Dual-Inhibition of mTOR and Bcl-2 Enhances the Anti-tumor Effect of Everolimus against Renal Cell Carcinoma In Vitro and In Vivo. | 2019 |
2 |
| 5 |
30369518 | Interleukin-6 induces drug resistance in renal cell carcinoma. | 2018 Dec 8 |
1 |
| 6 |
30651932 | Second-line treatment after sunitinib therapy in patients with renal cell carcinoma: a comparison of axitinib and mammalian target of rapamycin inhibitors. | 2018 Dec 11 |
1 |
| 7 |
27395374 | Expression and prognostic significance of VEGF and mTOR pathway proteins in metastatic renal cell carcinoma patients: a prognostic immunohistochemical profile for kidney cancer patients. | 2017 Mar |
1 |
| 8 |
27893461 | Dual modulation of MCL-1 and mTOR determines the response to sunitinib. | 2017 Jan 3 |
1 |
| 9 |
27958294 | Targeted therapy: Sunitinib modulates MCL-1 and mTOR signalling. | 2017 Feb |
1 |
| 10 |
28413468 | Antitumor effect of sunitinib in human prostate cancer cells functions via autophagy. | 2017 Apr |
1 |
| 11 |
28672196 | Contrast-Enhanced CT Density Predicts Response to Sunitinib Therapy in Metastatic Renal Cell Carcinoma Patients. | 2017 Aug |
1 |
| 12 |
28903416 | Overriding TKI resistance of renal cell carcinoma by combination therapy with IL-6 receptor blockade. | 2017 Aug 15 |
1 |
| 13 |
28993730 | Molecular Guided Therapy Provides Sustained Clinical Response in Refractory Choroid Plexus Carcinoma. | 2017 |
1 |
| 14 |
29262588 | Mitochondrial phosphoenolpyruvate carboxykinase (PEPCK-M) regulates the cell metabolism of pancreatic neuroendocrine tumors (pNET) and de-sensitizes pNET to mTOR inhibitors. | 2017 Nov 28 |
1 |
| 15 |
27031198 | [Systemic therapy of metastatic renal cell carcinoma]. | 2016 Apr |
1 |
| 16 |
27103123 | Phase I study of safety and tolerability of sunitinib in combination with sirolimus in patients with refractory solid malignancies and determination of VEGF (VEGF-A) and soluble VEGF-R2 (sVEGFR2) in plasma. | 2016 Jun |
1 |
| 17 |
27538132 | [Sunitinib induces autophagy via suppressing Akt/mTOR pathway in renal cell carcinoma]. | 2016 Feb 18 |
5 |
| 18 |
27990160 | The Roles of PI3K/AKT/mTOR and MAPK/ERK Signaling Pathways in Human Pheochromocytomas. | 2016 |
1 |
| 19 |
29263493 | [Sunitinib induces autophagy via suppressing Akt/mTOR pathway in renal cell carcinoma]. | 2016 Aug 18 |
5 |
| 20 |
25444514 | Molecular analysis of sunitinib resistant renal cell carcinoma cells after sequential treatment with RAD001 (everolimus) or sorafenib. | 2015 Feb |
1 |
| 21 |
25862847 | Targeting mTOR and AREG with everolimus, sunitinib and sorafenib in HPV-positive and -negative SCC. | 2015 Apr |
1 |
| 22 |
25963382 | Targeted therapies for treatment of renal cell carcinoma: recent advances and future perspectives. | 2015 Aug |
1 |
| 23 |
24018642 | Systematic combination screening reveals synergism between rapamycin and sunitinib against human lung cancer. | 2014 Jan 1 |
1 |
| 24 |
24800947 | Sunitinib re-challenge in advanced renal-cell carcinoma. | 2014 Sep 9 |
1 |
| 25 |
25193011 | Renal cell carcinoma with intramyocardial metastases. | 2014 Sep 6 |
1 |
| 26 |
25764782 | [The newest perspectives on diagnostic methods and treatment of insulinoma]. | 2014 |
1 |
| 27 |
25841679 | Emerging therapies for pancreas neuroendocrine cancers. | 2013 Sep |
1 |
| 28 |
21445973 | Long-term exposure of gastrointestinal stromal tumor cells to sunitinib induces epigenetic silencing of the PTEN gene. | 2012 Feb 15 |
2 |
| 29 |
21735145 | Maximising the duration of disease control in metastatic renal cell carcinoma with targeted agents: an expert agreement. | 2012 Sep |
2 |
| 30 |
22338018 | New strategies for advanced neuroendocrine tumors in the era of targeted therapy. | 2012 Apr 1 |
1 |
| 31 |
22532600 | Modulation of Akt/mTOR signaling overcomes sunitinib resistance in renal and prostate cancer cells. | 2012 Jul |
2 |
| 32 |
21625184 | Efficacy of sunitinib re-exposure after failure of an mTOR inhibitor in patients with metastatic RCC. | 2011 |
1 |
| 33 |
21672194 | Evolving diagnostic and treatment strategies for pancreatic neuroendocrine tumors. | 2011 Jun 14 |
1 |
| 34 |
20053726 | Sunitinib induces apoptosis and growth arrest of medulloblastoma tumor cells by inhibiting STAT3 and AKT signaling pathways. | 2010 Jan |
1 |
| 35 |
20471160 | mTOR inhibition by everolimus counteracts VEGF induction by sunitinib and improves anti-tumor activity against gastric cancer in vivo. | 2010 Oct 28 |
4 |
| 36 |
20625300 | Novel targeted therapy for advanced renal carcinoma: trials in progress. | 2010 Sep |
1 |
| 37 |
21067536 | Antiangiogenic therapy for breast cancer. | 2010 |
1 |
| 38 |
19412427 | In vivo antitumor and antimetastatic activity of sunitinib in preclinical neuroblastoma mouse model. | 2009 May |
1 |
| 39 |
19467916 | FLT3 inhibition and mechanisms of drug resistance in mutant FLT3-positive AML. | 2009 Jun |
2 |
| 40 |
17935273 | Sunitinib, sorafenib and mTOR inhibitors in renal cancer. | 2007 Sep |
1 |
| 41 |
16916320 | Effect of SU11248 on gastrointestinal stromal tumor-T1 cells: enhancement of growth inhibition via inhibition of 3-kinase/Akt/mammalian target of rapamycin signaling. | 2006 Sep |
2 |
| 42 |
16995874 | ZD6474 induces growth arrest and apoptosis of GIST-T1 cells, which is enhanced by concomitant use of sunitinib. | 2006 Dec |
1 |